Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 286

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Metastatic osteosarcoma at diagnosis: Prognostic factors and long‐term outcome—The French pediatric experience

Mialou, Valerie, Philip, Thierry, Kalifa, Chantal, Perol, David, Gentet, Jean‐Claude, Marec‐Berard, Perrine, Pacquement, Helene, Chastagner, Pascal, Defaschelles, Anne‐Sophie, Hartmann, Olivier · 2005 · Cancer

Abstract

BACKGROUND: The objective of this report was to estimate long‐term outcome and prognostic factors in children and adolescents who presented with metastatic osteosarcoma at diagnosis. Patients were treated in six French pediatric oncology centers with surgery and multiagent chemotherapy, mainly with high‐dose methotrexate. Their medical records were reviewed retrospectively. METHODS: The medical records of patients who were treated for metastatic osteosarcoma from 1987 to 2000 were reviewed. Patients were treated with the chemotherapy regimens recommended for nonmetastatic disease in children (the French Society of Pediatric Oncology OS 87 and OS 94 protocols) or, in a few patients, with other chemotherapy regimens. Surgical excision of the primary tumor and, when possible, of all metastatic sites was performed based on a personalized assessment of each patient's situation. RESULTS: Seventy‐eight patients age < 20 years were treated. Forty‐six patients (59%) had only 1 metastatic site (35 to the lungs and 11 to bone). Twenty‐eight patients (36%) achieved a complete remission after combination chemotherapy and surgery. The event‐free survival and overall survival rates at 5 years were 14% and 19%, respectively. To date, 14 patients (18%) have remained alive with a median follow‐up of 112 months. Pretreatment features associated with a shorter event‐free survival in the multivariate analysis were metastasis to at least two organs and high alkaline phosphatase level. Patients with at least 1 of these poor prognostic factors had a 2.6% event‐free survival rate at 5 years despite treatment. CONCLUSIONS: The survival of patients with metastatic osteosarcoma were treated with conventional chemotherapy and surgery remained very poor. Patients should be classified into different prognostic groups and treated accordingly. New therapeutic approaches are warranted to improve the prognosis for patients with the most severe disease. Cancer 2005. © 2005 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.21263

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 286

Metadata

Authors
Mialou, V., Philip, T., Kalifa, C., Perol, D., Gentet, J., Marec‐Berard, P., Pacquement, H., Chastagner, P., Defaschelles, A., & Hartmann, O.
Venue
Cancer
Publisher
Wiley
Published
2005-07-13
Volume
104
Issue
5
Pages
1100-1109
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2046548272
Cited by
286
References
28
FWCI
4.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.